In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Surgery Partners Inc (NASDAQ: SGRY) closed at $22.22 up 0.73% from its previous closing price of $22.06. In other words, the price has increased by $0.73 from its previous closing price. On the day, 0.68 million shares were traded. SGRY stock price reached its highest trading level at $22.4 during the session, while it also had its lowest trading level at $21.99.
Ratios:
For a deeper understanding of Surgery Partners Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.42 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.43. For the most recent quarter (mrq), Quick Ratio is recorded 1.73 and its Current Ratio is at 1.89. In the meantime, Its Debt-to-Equity ratio is 2.22 whereas as Long-Term Debt/Eq ratio is at 2.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on December 16, 2024, initiated with a Buy rating and assigned the stock a target price of $30.
On October 14, 2024, UBS started tracking the stock assigning a Buy rating and target price of $38.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 14 ’25 when Baldock Jennifer sold 612 shares for $23.94 per share. The transaction valued at 14,651 led to the insider holds 236,047 shares of the business.
Burkhalter Danielle sold 74 shares of SGRY for $1,760 on Mar 14 ’25. The Chief Human Resources Officer now owns 44,839 shares after completing the transaction at $23.78 per share. On Mar 14 ’25, another insider, Webb William Trenton, who serves as the American Group President of the company, sold 138 shares for $23.70 each. As a result, the insider received 3,271 and left with 74,521 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGRY now has a Market Capitalization of 2847715072 and an Enterprise Value of 8319911424. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.90 while its Price-to-Book (P/B) ratio in mrq is 1.64. Its current Enterprise Value per Revenue stands at 2.622 whereas that against EBITDA is 13.234.
Stock Price History:
The Beta on a monthly basis for SGRY is 1.83, which has changed by -0.27739835 over the last 52 weeks, in comparison to a change of 0.17774606 over the same period for the S&P500. Over the past 52 weeks, SGRY has reached a high of $33.97, while it has fallen to a 52-week low of $18.87. The 50-Day Moving Average of the stock is -1.10%, while the 200-Day Moving Average is calculated to be -6.82%.
Shares Statistics:
For the past three months, SGRY has traded an average of 1.48M shares per day and 1230320 over the past ten days. A total of 128.19M shares are outstanding, with a floating share count of 75.86M. Insiders hold about 40.81% of the company’s shares, while institutions hold 71.32% stake in the company. Shares short for SGRY as of 1751241600 were 11426092 with a Short Ratio of 7.71, compared to 1748563200 on 9364681. Therefore, it implies a Short% of Shares Outstanding of 11426092 and a Short% of Float of 18.91.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of Surgery Partners Inc (SGRY) in the stock market is under the watchful eye of 11.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.21, with high estimates of $0.33 and low estimates of $0.06.
Analysts are recommending an EPS of between $1.21 and $0.47 for the fiscal current year, implying an average EPS of $0.85. EPS for the following year is $1.08, with 12.0 analysts recommending between $1.7 and $0.7.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $816.96M this quarter.It ranges from a high estimate of $830M to a low estimate of $785M. As of the current estimate, Surgery Partners Inc’s year-ago sales were $762.1MFor the next quarter, 12 analysts are estimating revenue of $838.47M. There is a high estimate of $883.6M for the next quarter, whereas the lowest estimate is $815.31M.
A total of 12 analysts have provided revenue estimates for SGRY’s current fiscal year. The highest revenue estimate was $3.4B, while the lowest revenue estimate was $3.32B, resulting in an average revenue estimate of $3.38B. In the same quarter a year ago, actual revenue was $3.11BBased on 12 analysts’ estimates, the company’s revenue will be $3.69B in the next fiscal year. The high estimate is $3.8B and the low estimate is $3.61B.
